Your browser doesn't support javascript.
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.
Gaitzsch, Erik; Passerini, Verena; Khatamzas, Elham; Strobl, Carolin D; Muenchhoff, Maximilian; Scherer, Clemens; Osterman, Andreas; Heide, Michael; Reischer, Anna; Subklewe, Marion; Leutbecher, Alexandra; Tast, Benjamin; Ruhle, Adrian; Weiglein, Tobias; Stecher, Stephanie-Susanne; Stemmler, Hans J; Dreyling, Martin; Girl, Philipp; Georgi, Enrico; Wölfel, Roman; Mateyka, Laura; D'Ippolito, Elvira; Schober, Kilian; Busch, Dirk H; Kager, Juliane; Spinner, Christoph D; Treiber, Matthias; Rasch, Sebastian; Lahmer, Tobias; Iakoubov, Roman; Schneider, Jochen; Protzer, Ulrike; Winter, Christof; Ruland, Jürgen; Quante, Michael; Keppler, Oliver T; von Bergwelt-Baildon, Michael; Hellmuth, Johannes; Weigert, Oliver.
  • Gaitzsch E; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Passerini V; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Khatamzas E; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Strobl CD; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Muenchhoff M; Max von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, LMU München, Germany.
  • Scherer C; German Center for Infection Research (DZIF), partner site Munich, Germany.
  • Osterman A; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, LMU Munich, Germany.
  • Heide M; COVID-19 Registry of the LMU Munich (CORKUM), University Hospital, LMU Munich, Germany.
  • Reischer A; Department of Medicine I, University Hospital, LMU Munich, Germany.
  • Subklewe M; Max von Pettenkofer Institute & Gene Center, Virology, National Reference Center for Retroviruses, LMU München, Germany.
  • Leutbecher A; German Center for Infection Research (DZIF), partner site Munich, Germany.
  • Tast B; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Ruhle A; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Weiglein T; Gene Center, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, Germany.
  • Stecher SS; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Stemmler HJ; Gene Center, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, Germany.
  • Dreyling M; German Cancer Consortium (DKTK), Munich, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Girl P; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Georgi E; Gene Center, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, Germany.
  • Wölfel R; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Mateyka L; Gene Center, Laboratory for Translational Cancer Immunology, Ludwig-Maximilians-Universität München, Germany.
  • D'Ippolito E; German Center for Infection Research (DZIF), partner site Munich, Germany.
  • Schober K; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Busch DH; Department of Medicine II, University Hospital, LMU Munich, Germany.
  • Kager J; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Spinner CD; Department of Medicine III, University Hospital, LMU Munich, Germany.
  • Treiber M; Bundeswehr Institute of Microbiology, Munich, Germany.
  • Rasch S; Bundeswehr Institute of Microbiology, Munich, Germany.
  • Lahmer T; Bundeswehr Institute of Microbiology, Munich, Germany.
  • Iakoubov R; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Germany.
  • Schneider J; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Germany.
  • Protzer U; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Germany.
  • Winter C; Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Germany.
  • Ruland J; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany.
  • Quante M; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany.
  • Keppler OT; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Munich, Germany.
  • von Bergwelt-Baildon M; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany.
  • Hellmuth J; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany.
  • Weigert O; Technical University of Munich, School of Medicine, University Hospital Rechts der Isar, Department of Internal Medicine II, Munich, Germany.
Hemasphere ; 5(7): e603, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1301392
ABSTRACT
The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas. The control cohort consisted of age- and sex-matched patients without lymphoma who were hospitalized because of COVID-19. We performed detailed clinical analyses, in-depth cellular and molecular immune profiling, and comprehensive virological studies in 12 patients with available biospecimens. B-cell depleted lymphoma patients had more severe and protracted clinical course (median hospitalization 88 versus 17 d). All patients actively receiving immunochemotherapy (n = 5) required ICU support including long-term mechanical ventilation. Neutrophil recovery following granulocyte colony stimulating factor stimulation coincided with hyperinflammation and clinical deterioration in 4 of the 5 patients. Immune cell profiling and gene expression analysis of peripheral blood mononuclear cells revealed early activation of monocytes/macrophages, neutrophils, and the complement system in B-cell depleted lymphoma patients, with subsequent exacerbation of the inflammatory response and dysfunctional interferon signaling at the time of clinical deterioration of COVID-19. Longitudinal immune cell profiling and functional in vitro assays showed SARS-CoV-2-specific CD8+ and CD4+ T-effector cell responses. Finally, we observed long-term detection of SARS-CoV-2 in respiratory specimens (median 84 versus 12 d) and an inability to mount lasting SARS-CoV-2 antibody responses in B-cell depleted lymphoma patients. In summary, we identified clinically relevant particularities of COVID-19 in lymphoma patients receiving B-cell depleting immunochemotherapies.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Hemasphere Year: 2021 Document Type: Article Affiliation country: HS9.0000000000000603

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Journal: Hemasphere Year: 2021 Document Type: Article Affiliation country: HS9.0000000000000603